U.S. STOCKS ON THE MOVE-Walmart, Lockheed Martin, UnitedHealth Group
Biohaven drops after FDA extends review period for genetic disease drug
Brief: Biohaven Says FDA Extends PDUFA Date Of Biohaven's Troriluzole NDA For Rare Disease Spinocerebellar Ataxia
Biohaven Ltd reports results for the quarter ended March 31 - Earnings Summary
Brief: Biohaven Q1 Net Income USD -221.677 Million
U.S. STOCKS ON THE MOVE-Nvidia, Sabre, Biohaven
U.S. STOCKS ON THE MOVE-Marriott, Wells Fargo, Insulet
U.S. STOCKS ON THE MOVE-Domino's Pizza, Eli Lilly, Revvity
Brief: Biohaven Announces Investment Up To $600 Mln By Oberland Capital
Biohaven jumps after securing up to $600 million investment from Oberland Capital
Brief: Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The Board
U.S. STOCKS ON THE MOVE-Mobileye, Visionary Holdings, Wolfspeed
Biohaven drops as Morgan Stanley cuts PT after bipolar drug failure
U.S. STOCKS ON THE MOVE-THOR Industries, TG Therapeutics, Target
U.S. STOCKS ON THE MOVE-Melco Resorts, Chipotle, Allegro
Biohaven slides on wider-than-expected quarterly loss
Focus: Next generation weight loss drugs aim to save muscle
Factbox: Fat, not muscle: drugmakers in race for next weight-loss breakthrough
U.S. STOCKS ON THE MOVE-Marriott International, Coty, Carlyle Group